NCT05663827View on ClinicalTrials.gov

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

January 1, 2020

Study Completion Date

November 30, 2022

Conditions
Steroid Refractory GVHD
Interventions
DRUG

Ruxolitinib

A dosage of 5mg once daily will be applied as initiation. After one week use, dose escalation or de-escalation would depend on clinical response.

Trial Locations (1)

333

Chang Gung Memorial Hospital, Taoyuan District

All Listed Sponsors
lead

Yi-Lun Wang

OTHER

NCT05663827 - Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease | Biotech Hunter | Biotech Hunter